Related references
Note: Only part of the references are listed.M-Ras/Shoc2 signaling modulates E-cadherin turnover and cell-cell adhesion during collective cell migration
Pradeep Kota et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling
Manuel Sanclemente et al.
CANCER CELL (2018)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis
Lucy C. Young et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Further evidence that variants in PPP1CB cause a rasopathy similar to Noonan syndrome with loose anagen hair
Regina M. Zambrano et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2017)
Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses
Angelika Riedl et al.
JOURNAL OF CELL SCIENCE (2017)
Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling
Simon J. Cook et al.
FEBS JOURNAL (2017)
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Pasi A. Janne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Decoding the selectivity of eIF2α holophosphatases and PPP1R15A inhibitors
Marta Carrara et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2017)
RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
Ting Jin et al.
NATURE COMMUNICATIONS (2017)
Decoding the selectivity of eIF2α holophosphatases and PPP1R15A inhibitors
Marta Carrara et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2017)
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant et al.
PLOS ONE (2017)
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald et al.
CELL (2017)
Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy
Erin M. Higgins et al.
JCI INSIGHT (2017)
Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras
Tim Wang et al.
CELL (2017)
A Novel Rasopathy Caused by Recurrent De Novo Missense Mutations in PPP1CB Closely Resembles Noonan Syndrome with Loose Anagen Hair
Karen W. Gripp et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2016)
Negative feedback regulation of the ERK1/2 MAPK pathway
David Lake et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Strategies to make protein serine/threonine (PP1, calcineurin) and tyrosine phosphatases (PTP1B) druggable: Achieving specificity by targeting substrate and regulatory protein interaction sites
Wolfgang Peti et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes
Ana Herrero et al.
CANCER CELL (2015)
Inhibition of RAF lsoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng et al.
CANCER CELL (2015)
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
Zhan Yao et al.
CANCER CELL (2015)
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Julian Downward
CLINICAL CANCER RESEARCH (2015)
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
Steven R. Whittaker et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Regulation of RAF protein kinases in ERK signalling
Hugo Lavoie et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit
Indrajit Das et al.
SCIENCE (2015)
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Aaron N. Hata et al.
CANCER DISCOVERY (2015)
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Christopher J. Caunt et al.
NATURE REVIEWS CANCER (2015)
Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
Piro Lito et al.
CANCER CELL (2014)
Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged
Paul B. Chapman et al.
CANCER CELL (2014)
The RhoGEF GEF-H1 Is Required for Oncogenic RAS Signaling via KSR-1
Jane Cullis et al.
CANCER CELL (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer
Nina Schoenhuber et al.
NATURE MEDICINE (2014)
Targeting RAS-ERK signalling in cancer: promises and challenges
Ahmed A. Samatar et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Chong Sun et al.
CELL REPORTS (2014)
RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
Simona Lamba et al.
CELL REPORTS (2014)
Challenges and Opportunities in the Development of Protein Phosphatase-Directed Therapeutics
Sofie De Munter et al.
ACS CHEMICAL BIOLOGY (2013)
The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance
Matthew J. Sale et al.
BIOCHEMICAL JOURNAL (2013)
That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance
Matthew J. Sale et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation
Kanae Sato et al.
CANCER SCIENCE (2013)
Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling
Alyson K. Freeman et al.
MOLECULAR CELL (2013)
An MRAS, SHOC2, and SCRIB Complex Coordinates ERK Pathway Activation with Polarity and Tumorigenic Growth
Lucy C. Young et al.
MOLECULAR CELL (2013)
IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors
Katherine L. Jameson et al.
NATURE MEDICINE (2013)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
miRNA-34 Prevents Cancer Initiation and Progression in a Therapeutically Resistant K-ras and p53-Induced Mouse Model of Lung Adenocarcinoma
Andrea L. Kasinski et al.
CANCER RESEARCH (2012)
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
Giorgia Migliardi et al.
CLINICAL CANCER RESEARCH (2012)
SHOC2 and CRAF Mediate ERK1/2 Reactivation in Mutant NRAS-mediated Resistance to RAF Inhibitor
Fred M. Kaplan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
Rafael B. Blasco et al.
CANCER CELL (2011)
C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D
Florian A. Karreth et al.
CANCER DISCOVERY (2011)
Endothelial SUR-8 Acts in an ERK-Independent Pathway During Atrioventricular Cushion Development
Jing Yi et al.
DEVELOPMENTAL DYNAMICS (2010)
Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
Daniel A. Ritt et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Impaired Binding of 14-3-3 to C-RAF in Noonan Syndrome Suggests New Approaches in Diseases with Increased Ras Signaling
Manuela Molzan et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim
Jieru Meng et al.
PLOS ONE (2010)
The extended PP1 toolkit: designed to create specificity
Mathieu Bollen et al.
TRENDS IN BIOCHEMICAL SCIENCES (2010)
Raf-1 Addiction in Ras-Induced Skin Carcinogenesis
Karin Ehrenreiter et al.
CANCER CELL (2009)
Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair
Viviana Cordeddu et al.
NATURE GENETICS (2009)
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
Michel DuPage et al.
NATURE PROTOCOLS (2009)
Positive regulation of A-RAF by phosphorylation of isoform-specific hinge segment and identification of novel phosphorylation sites
Angela Baljuls et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Germline gain-of-function mutations in RAF1 cause Noonan syndrome
M. Abdur Razzaque et al.
NATURE GENETICS (2007)
The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition
S. Meloche et al.
ONCOGENE (2007)
A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity
P Rodriguez-Viciana et al.
MOLECULAR CELL (2006)
The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase
MJ Martin et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Regulation of raf-1 by direct feedback phosphorylation
MK Dougherty et al.
MOLECULAR CELL (2005)
Regulation of Raf-1 activation and signalling by dephosphorylation
AS Dhillon et al.
EMBO JOURNAL (2002)
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
EL Jackson et al.
GENES & DEVELOPMENT (2001)
Share Paper
